Combinatorial biosynthesis of polyketide synthases through genetic engineering should provide complex compounds as drug development candidates. Different strategies are currently being evaluated to create libraries of new compounds. The number of different compounds in such libraries and the quantities that can be made using combinatorial strategies will determine the impact of this technology on the pharmaceutical industry.